Gilead forecasts FY26 Yeztugo revenue at about $1 billion

Reuters2026/08/04 22:11

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Gilead guided for FY26 HIV revenue growth of 9%-10% year over year, led by Biktarvy, Yeztugo, Descovy.
FY26 Yeztugo revenue expected near USD 1 billion; Q2 sales reached USD 232 million, up 40% quarter over quarter.
Cell therapy revenue forecast to fall by a mid-teens percentage in FY26; Q2 sales were USD 417 million, down 14% year over year.
Veklury revenue outlook set at about USD 300 million for FY26; Q2 sales were USD 23 million, down 81% year over year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Gilead forecasts FY26 Yeztugo revenue at about $1 billion

You may also like

Crypto prices